Immunology

Case Western Reserve University School of Medicine, USA

Immunology

Vaccinogen Inc., USA

cancer vaccines

Associate Professor Dr. Gamil G. S. Zeedan obtained Ph.D. Virology ,Cairo University Egypt , MVSCs Virology, Cairo University. BVSCs , Cairo University . 2015 up to date Assistant Professor of Microbiology and Virology at Clinical laboratory Sciences at College of Applied Medical Sciences Shaqra University Saudi Arabia,2014 -2015 Associate Professor of Microbiology at National Research Center Ministry of High Education - Cairo Egypt -Cairo Egypt, .10-2013 Assistant Professor of Microbiology at Faculty of Medicine and Applied Medical Sciences –Northern Border University (NBU)- KSA) for 3acdemic years 2007- 2010,Assistant Researcher at National Research Center- Ministry of High Education - Cairo Egypt. He teaching the following curriculum,Medical Microbiology and Virology, Diagnostic Microbiology ,Clinical Rotation of Microbiology and Clinical Rotation Immunology & Virology. 2015- up-to-date Microbiology at Clinical laboratory Sciences at College of Applied Medical Sciences Shaqra University Saudi Arabia . 2010-52013 Microbiology in faculty of Medicine and Applied medical Sciences - Northern Border University, Saudi Arabia. Participate in teaching Medical Microbiology ( Virology ) MICM 311 courses for 3rd-year Medical students (3 hours/week).Participate in teaching Diagnostic Microbiology

Microbiology and Virology

R. P. Iyer, (Kris), Ph.D., FRSC is the co-founder and Chief Scientific Officer of Spring Bank Pharmaceuticals. He has more than 25 years’ experience in Biotechnology industry in drug discovery and development in diverse therapeutic areas including antivirals, inflammation and immune-oncology. Kris is a leading innovator in the fields of nucleic acid chemistry, bioorganic chemistry and pharmaceutical sciences with over 100 publications and 200 issued, as well as, filed US and international patents. Prior to Spring Bank, Kris was the co-founder and VP of Discovery of Origenix Technologies and also served as Associate Director of Antisense Discovery at Hybridon, Inc. He currently serves on the Board of Directors of Spring Bank Pharmaceuticals and is a member of the Scientific Advisory Board of Oligomerix, Inc., NY.

Cancer Immunology

Dr. Jerald C. Sadoff is currently the Head of Early Development of the Crucell Vaccine Institute which is the Center of Excellence for Vaccine Development for Johnson & Johnson Companies Worldwide. Dr. Sadoff has spent his entire career developing vaccines against a large number of bacterial, viral and parasitic diseases, 11 of which have been licensed for human use and several currently are in Phase IIB and Phase III clinical trials. He currently serves on several IPCAVD Scientific Advisory Boards for NIH sponsored HIV vaccine efforts and is on the NIAID AIDS Vaccine Research Working Group. Over the last 35 years, he has authored over 350 articles, book chapters, and abstracts and has 18 issued patents

Vaccine Development

Pierre A. MORGON is Chief Executive Officer of MRGN Advisors and Regional Partner for Switzerland at Mérieux Développement, an evergreen investment structure focused on medical devices, in vitro diagnostics and patient management services. He is also Chairman of the Board of Virometix since January 2017, a company developing proprietary synthetic nanoparticle platform in vaccines and immunotherapeutic drugs for viral diseases and cancer, as well as Non-Executive Director to the Board of Theradiag since March 2012, a company focusing on in vitro diagnostics in auto-immunity, infectious diseases and allergy, and Non-Executive Director to the Board of Eurocine Vaccines since December 2013, a company dedicated to developing nasal vaccines. He joined the board of Virometix as chairman in January 2017

Vaccines and Immunotherapeutic drugs for Viral diseases and Cancer

Benoit Tano, M.D. is a specialist, pioneer, and the Minneapolis area’s foremost expert in the field of Integrative Immunity. Dr. Tano is the founder of Integrative Immunity Health System, PC located in Edina, Minnesota. He is Johns Hopkins-fellowship trained in allergy and clinical immunology and authored the number one bestselling book, The Layman’s Guide to Integrative Immunity (2016). He combines his vast expertise in allergy and clinical immunology and in hormone imbalance syndrome to treat the root causes of 21st-century chronic diseases.

Clinical Immunology

Professor Andrzej K. Siwicki, VMD, Ph.D., DSc is a Head of Department Microbiology and Clinical Immunology, Faculty of Veterinary Medicine, University of Warmia and Mazury and Department of Pathology and Immunology IFI in Olsztyn, Poland. He is author of over 500 original papers in reputed journals and about 200 scientific communications (index-h 32, index of citation: 4502). His fields of interest are modulation of defence mechanisms and protection against diseases by natural and synthetic products in animals, influence of pollutants on the cell-mediated immunity and restoration of immunity after suppression induced by xenobiotics. Developed a new possibility in the comparative immunotoxicology for control of effect of xenobiotics and pharmaceutical products on the defence mechanisms and protection against diseases. He attended scientific missions in USA, Japan, France and Israel, was a co-ordinator of USDA and FAO projects and he is professor conferring of 14 PhDs and 4 DSc.

Microbiology and Clinical Immunology

1998-2003 Member of the Institut Universitaire de France Junior, then Honorary position 1998-2000 Senior Scientist at the Mind Body Institute of Harvard Medical School, USA 31/05/1995 Habilitation for directing research in Natural Sciences, University Lille 1 3/02/1993 Ph.D. in Life Science and Health, University Lille 1

Immunology

Prof. Dr. Ignat Ignatov was born on January 1, 1963 in the town of Teteven, Bulgaria. Тhe family Ignatov is from village of Gradina, region of Pleven, Bulgaria. In 1976 descrebes a phenomenon in which little apertures act like optic lenses. In 1989 Ignatov majored in physics from “Kliment Ohridski” Sofia University with master degree. In the same year he began his professional work in the sphere of medical biophysics. In 1996 he founded the Scientific and Research Center of Medical Biophysics (SRCMB) of which he is also an owner. Prof. Dr. Ignat Ignatov was a consultant of the National Center of Public Health (NCPH) at the Ministry of Health until 2003. The Bulgarian scientist is involved in research projects for the study of biophysical and medical effects in the application of alternative methodics for the influencing of human health. Bulgaria has a Health Act, which authorizes the practice of non-conventional (alternative) methodics. Trainings are carried out. From 2007 Ignat Ignatov is honorable doctor in European Academy of Natural Sciences (Germany). From 2013 he is Doctor of Science and Professor in The Russian Academy for Natural History. Prof. Ignatov is Chief Editor of two US journals. The first is Journal of Medicine, Physiology and Biophysics. The second is Journal of Health, Medicine and Nursing. The Bulgarian scientist is editor in chief in European Journal of Molecular Biotechnology, European Journal of Medicine - international bilingual scientific Journal and Research & Reviews in Biosciences.

Medicine, Physiology and Biophysics

He graduated from Hacettepe University Faculty of Medicine in 1990. He completed his specialist education in Hacettepe University Faculty of Medicine Internal Medicine Department in 1995 and his branch of Medical Oncology Unit in 1999. Associate Professor in 2000, Professor in 2007. Between 2004 and 2006, she worked as a guest lecturer at the MD Anderson Cancer Center in Houston, Texas, USA to study breast cancer. Hacettepe University Institute of Health Sciences in 2013 and Hacettepe University Cancer Institute in 2013-2016 and Hacettepe University Internal Medicine Department and Medical Oncology Department in 2013-2015.

Oncology

Sr. Research Associate at University of Texas Health Science Center at Houston Former Research Assistant at Baylor College of Medicine Former Research Assistant at New York Medical College

Epidemiolgy, Biochemistry

Dr. Luiz Werber-Bandeira is a physician with emphasis in Clinical Immunology, head of Clinical Immunology at the Santa Casa da Misericórdia Hospital and responsible for all the professional team that compose the clinical body of Imunoderm, in the Botafogo neighborhood and Ilha do Governador, Rio de January. For 36 years in the profession, he has done Post-Doctorate in Immuno-Genetics from the Oswaldo Cruz Foundation (FioCruz-RJ), a master's degree and a PhD from the Federal University of Rio de Janeiro (UFRJ). He is coordinator of the Postgraduate Course in Immunology and Clinical and Laboratory Allergy, organizer responsible for the Research Line of the Clinical and Experimental Immunology Unit of the Santa Casa da Misericórdia in Rio de Janeiro, as well as a professor who participates in the line of research in PhotoDermatology and Immunology of UFRJ.

PhotoDermatology and Immunology

Dr. Ahmed Shoker was born in Egypt, graduated from the University of Alexandria, Egypt and moved to Canada in 1981. He received his training in general medicine at the University of British Columbia, Vancouver, Canada. He received his training in nephrology and transplantation at the University of Toronto where he received his fellowship training in transplantation between 1987 and1990. He then moved to the University of Saskatchewan. Currently, he is a Professor of Medicine and Nephrology at the University of Saskatchewan. He is the Medical Director of the provincial Transplant Program. His research interests include clinical trials and basic research in the field of immunosuppression and inflammation.

His current interest is the relationship between cardiovascular disease risk factors and inflammatory markers before and after kidney transplantation

As a Professor of Clinical and Chemical Pathology with an MD degree from the Faculty of Medicine, Cairo University and as the current Head of the Electron Microscopic Research Department in the Theodor Bilharz Research Institute , a medical research institution affiliated to the Egyptian Ministry of Higher Education and Scientific Research I focus my research on the role of immune cells in combating hepatic diseases caused by helminthic (schistosomiasis), bacterial or viral infections (hepatitis virus ) using electron microscopy and immunoelectron microscopy to visualize cellular changes accompanying such diseases. I was involved in scientific cooperative research with German and French institutions and I am very open to different cultures. I speak fluent English, German, French, and Arabic.

I focus my research on the role of immune cells in combating hepatic diseases caused by helminthic (schistosomiasis), bacterial or viral infections (hepatitis virus ) using electron microscopy and immunoelectron microscopy to visualize cellular changes accompanying such diseases.

Qingxian Lu received his Bachelor's degree from Shandong University, Master's from Peking Union Medical College, Beijing, and Ph. D.The University of Texas.

His interests are focused on elucidating molecular mechanisms of three closely-related receptor tyrosine kinases, called Tyro3, Axl and Mertk (TAM), in the regulation of phagocytic activity in professional and non-professional phagocytes, particularly in the retinal pigmental epithelium cells in the eye. Phagocytic clearance of the spent photoreceptor distal outer segment (OS) tips by the retinal pigmental epithelium (RPE) cells is essential to maintain photoreceptor homeostasis. Failure of RPE phagocytosis of the OS leads to retinitis pigmentosa (RP). Mutation in the Mertk receptor tyrosine kinase causes photoreceptor degeneration. To understand the molecular role of Mertk in phagocytosis, we have used Mertk mutated RPE cells as a model to identify Mertk downstream target genes or signaling molecules that are involved in regulation of the phagocytic events.

Andrew Wilber has expertise in hematology and immunology. His laboratory is interested in understanding the role of the tumor microenvironment in suppressing anti-tumor immunity. Current efforts are examining deficiencies in natural anti-tumor immunity in patients with advanced kidney cancer. Specifically, his group is studying alterations in natural killer cells within the blood and tumor of these patients. These changes prevent natural killer cells from destroying kidney tumor cells. Prevention of these processes may be an important goal of future tumor therapy.

Tumor, Tumor Immunology

Young Kwang Chae is currently an Assistant Professor of Medicine, Division of Hematology and Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine & Co-Director of Developmental Therapeutics Program of the Division of Hematology Oncology. He is also an Co-Chair of Multi-Histology Disease Team Meeting, Robert H. Lurie Comprehensive Cancer Center. He won Many Awards such as Samsung Scholarship: tuition and living expense support for the Johns Hopkins University MPH program, October 2004 Johns Hopkins Bloomberg School of Public Health Student Conference Award, April 2006 First place, Clinical Research Award, Albert Einstein Medical Center, May 2009; for outstanding poster presented on the Research Recognition Day and many more

personalized cancer therapy, precision medicine, novel combination cancer therapy, targeted therapy, immunotherapy, biomarker studies, novel drug development, novel drug delivery systems, adaptive clinical trials design, cell signaling pathways, and immune checkpoint pathways.

Masoud H. Manjili is an Associate Professor in the department of Microbiology & Immunology in the VCU School of medicine, Massey Cancer center, USA. He obtained his PhD from Sydney University in 1996. He was also an affiliated member in Roswell Park Cancer Institute (2003-2004). He is an associate Editor of Journal Frontiers in Tumor immunology. Also an Editorial Board Member of Journal of Molecular & Genetic Medicine. He also serves as an Manaing editor of American Association of Immunologists; American Association for Cancer Research; Society for Immunotherapy of Cancer; Society for Thermal Medicine; American Association for the Advancement of Science; International Society of Translational Medicine.

Immunotherapy and cancer dormancy; Tumor Immunology; Tumor Immunoediting; Tumor Recurrence and Metastasis

In 2001, Dr. Han obtained his Ph.D degree in clinical hematology from Chinese PLA Postgraduate Medical School, and worked in Dept. of Molecule & Immunology of Chinese PLA General Hospital. In 2003, he did postdoctoral work at the University College London. In 2006, he was promoted to professor of molecular and cellular biology. Now, he is the Director of Dept. of Molecular and Cellular Biology, Director of Clinical Translational Ward, the General Hospital of PLA. Since 2001, he focused on mechanism research involved in cancer-treatment resistance and clinical translation of cell therapy. He has published over 80 articles.

Cancer- Treatment resistance, Clinical translation of cell therapy

Dr William Cho is a Biomedical Scientist in Queen Elizabeth Hospital. He is a Chartered Scientist granted by the Science Council (UK), a Registered Chinese Medicine Practitioner (HK), Guest Professor of a number of Universities and a Fellow Member of several institutes, including the Institute of Biomedical Science (UK), Hong Kong Institute of Biomedical Science and Hong Kong Society for Molecular Diagnostic Sciences. Dr Cho has published over 200 peer-reviewed papers He serves as the editor-in-chief, editor and associate editor of a number of international medical journals. Dr Cho is also an international renowned grant reviewer of the Hope Funds for Cancer Research (USA), Cancer Research (UK), MRC Research Grant (UK), Health Research Board (Ireland), Science Foundation (Ireland), Istituto Toscano Tumori (Firenze), The Foundation Fournier-Majoie for Innovation (Brussels), National Medical Research Council (Singapore), The Medical Research Council (South Africa), and Academia Sinica Investigator Award (Taiwan), etc.

cancer, cancer diagnosis, treatment prediction and prognostication

Dr. Roza Nurieva is currently an Assistant Professor, Department of Immunology, Tenure-Track, The University of Texas MD Anderson Cancer Center, Houston, TX USA. She is also an Instructor, Department of Immunology, Division of Basic Science Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. she is honoured with an The Journal of Biological Chemistry/Herbert Tabor Young Investigator Award, International Cytokine and Interferon Society in 2015 & also published many articles in reputed journals.

Cancer, Immunology, Autoimmunity.

Dr Manal Mohamed Saber, has earned her PhD from Nottingham, UK. she is focusing on cancer studies, EMAP II, immune suppression, molecular, cellular and laboratory techniques at a high level. She received excellent training in molecular and cellular techniques at the highest international level and has previously worked with cancer and immunology studies. Her dedication to cure cancer got her involved in cancer studies

Cancer, Immunology, Cellular Immunology, Molecular Immunology

Charles J Malemud received the PhD from George Washington University in 1973 and completed postdoctoral studies at the State University of New York at Stony Brook in 1977. He is Professor of Medicine & Anatomy in the Division of Rheumatic Diseases and Senior Investigator in the Arthritis Research Laboratory at Case Western Reserve University School of Medicine. He has published more than 200 papers and reviews primarily in the field of chondrocyte biology. He is on the editorial board of several rheumatology, immunology and musculoskeletal journals and is Editor-in-Chief of the Journal of Clinical and Cellular Immunology.

Biology of the Musculoskeletal System Intracellular Signal Transduction Pathways Inflammation Pro-inflammatory, Anti-Inflammatory & Anabolic Cytokines Apoptosis Matrix metalloproteinases Osteoarthritis Rheumatoid Arthritis Fibromyalgia Autoimmune Disorders Research Interest

Sudhir Gupta is a Professor of Medicine, Pathology & Laboratory Medicine, and Microbiology & Molecular Genetics, Chief of the Division of Basic and Clinical Immunology, and the Director of the Jeffrey Modell Diagnostic Center in Primary Immunodeficiencies at the University of California, Irvine. He also serves as Director of Scientific Development at the Sass Foundation for Medical Research in New York. Dr Gupta received his medical and doctorate degrees from the King George's Medical College in Lucknow, India. Previous appointments include Associate Professor of Medicine and Immunology at the Weill Cornell Medical College, and Associate Member at the Sloan-Kettering Institute for Cancer Research, both in New York, New York. Dr Gupta is board certified in Clinical Immunology by the Royal College of Physicians and Surgeons of Canada; he is board certified in Allergy and Immunology, and Diagnostic Laboratory Immunology by the American Board of Allergy and Immunology. Dr Gupta is a Master of the American College of Physicians. Dr. Gupta has served on a number of committees for many leading governmental bodies and organizations, including the National Institutes of Health, the U.S. Food and Drug Administration, and the World Health Organization. Dr Gupta has made many original contributions in the field of cellular and molecular immunology as it relates to primary immunodeficiency diseases, AIDS, cancer research, and aging. These findings have been published in high-impact journals, including Science, Nature, the Proceedings of the National Academy of Sciences, the Journal of Experimental Medicine, the Journal of Clinical Investigation, the New England Journal of Medicine, and Aging Cell. Dr Gupta has published more than 500 scientific papers, invited reviews, and book chapters. He has edited 24 books in various areas of cellular, molecular, and applied immunology, including one on primary immunodeficiency.

Molecular signaling of apoptosis, Dendritic cell biology, B cell biology, Genetic basis of primary immunodeficiency diseases

Michael Tainsky is a molecular cell biologist who has been studying the molecular basis of human cancer for more than 30 years. In 1998, he came to the Karmanos Cancer Institute at Wayne State University School of Medicine after 13 years on the faculty of the University of Texas, M.D. Anderson Cancer Center in Houston, TX, and 8 years at NCI/NIH. He has studied the biological effects of oncogenes, tumor suppressor genes, and transcription factor on tumor cells; and in the Li-Fraumeni Cancer Syndrome, he studied the mechanisms of cellular immortalization. Recently, he extended his mechanistic cancer research to translational applications of genomics and proteomics to molecular diagnostics of ovarian cancer. For the past 10 years, his laboratory team has developed the epitope cloning technology and protein microarray immunoassays to detect tumor autoantibodies in patients’ sera. His Epitomics Biomarker Technology identifies the autoantigen biomarkers using novel informatics tools for the classification of patients. In 2009, he published a 330-page book as editor in the Methods in Molecular Biology Series from Humana Press entitled Tumor Biomarker Discovery. He was invited to guest edit Special Issues of the journal Cancer Biomarkers on Antibody Biomarkers and Biomarkers in Ovarian Cancer. Dr. Tainsky holds the Barbara and Fred Erb Chair in Cancer Genetics at the Barbara Ann Karmanos Cancer Institute. He is a professor in the Department of Oncology.

• Molecular genetic mechanisms by which normal cells become malignant • Pathway analysis of gene expression changes leading to cellular immortalization • Development of novel cancer diagnostic tests for early detection of cancer in the form of a complex blood test

Martin D’Souza has completed his PhD from the University of Pittsburgh, PA. He is the director of Graduate Programs at Mercer University, College of Pharmacy and Co-Director of the Center for Drug Delivery. He has published more than 80 manuscripts and is on the editorial board of several journals.

The D'Souza nanotechnology laboratory mainly focuses on the design of novel patented technologies to deliver nano vaccines via the oral, buccal, parenteral and microneedle based transdermal route. Examples include: viral vaccines such as influenza vaccines, HIV and human papilloma vaccines (HPV); bacterial vaccines such as pneumonia, meningitis, TB and typhoid; and cancer vaccines, such as breast, melanoma, prostate, liver and ovarian. Recently, we also have been involved in tissue bio-engineering- applications including the use of cell encapsulation and thermo-sensitive gels for transplantation of pancreatic cells in diabetes.

Ahmed Hegazi (or Ahmed Gaffer Hegazi; احمد جعفر حجازى) (born May 31, 1948) is currently a Professor of Microbiology and Immunology in the department of Zoonotic Diseases, National Research Center, Egypt. Prof. Hegazi received his masters degree in 1979, and his PhD in 1981. Hegazi's research work has been focused lately on bee products and their therapeutic effects. Hegazi Organized and contributed to national and international research projects since 1977 and up till now; he has been the principal investigator on multiple research projects within the National Research Center. He has published 166 scientific papers and articles in national and international journals. He also served on the board of multiple national and international scientific journals. Dr. Hegazi is also the president of the Egyptian Environmental Society for Uses and Production of Bee Products, secretary of the Egyptian Society of Apitherapy, secretary general of the African Federation of Apiculture Associations, and a member of the International Apitherapy Commission (APIMONDIA). Awards First Class Decoration of Excellence, Egypt, 1995 The Senior Scientist Prize of National Research Center, Cairo, Egypt, 1996 The National Scientific Prize In Biological Sciences, Egypt, 1990 The Scientific Prize of The National Research Center, Cairo, Egypt, 1989 The Second Best Research Paper Award, International Congress of Propolis, Bones Airs, Argentina, 2000 Main Speaker Award,10th Academic Conference, PRA and NAS (Nippon Apitherapy Soc.) Japan, 2006 2 Bronze medals from The International Innovation Fair of the Middle East, Kuwait, 2007 Patents Patent No. 8901 at 22/08/2006: A novel drug from natural products with new therapeutic modalities in treatment of psoriasis Patent No. 1005 at 02/01/2006: A novel drug from natural resources for controlling Fascioliasis Patent No. 270: at 01/06/2005: A novel drug from medicinal plants with antiatherosclerotic (hypocholesterolaemic), antioxidant and cardio protective properties. Patent No. 272: at 01/06/2005: A novel drug from natural resources with antiatherosclerotic (hypocholesterolaemic), antioxidant and cardio protective properties. Scientific Activities Editor in the following International Journals: Research Journal of Allergy, 2007 International Journal of Virology, 2007 Current Research In Tuberculosis, 2007 Research Journal of Veterinary Science, 2007 Research Journal of Microbiology, 2007 International Journal of Cancer Research, 2007 Research Journal of Medicinal plants, 2007 Referee in the following International Journals: Journal of Planta Medica, 2005 Journal of Evidence Based Complementary and Alternative Medicine, 2006 International Journal of Radiation Biology, 2007

Apitherapy, Immunology

Charles J Malemud is Associate Director of the Rheumatology Fellowship Training Program at University Hospitals Case Medical Center Professor of Medicine Anatomy Division of Rheumatic Diseases Case Western Reserve University School of Medicine Cleveland Ohio. He received the Ph.D. in Experimental Pathology from the Department of Biology at George Washington University Washington DC 1969-1973. He completed his BS in Biology at Long Island University 1966. He was elected to James Shannon Award Who´s Who in Healthcare and Medicine. He is serving as an editorial board member of 9 reputed journals and a peer-reviewer for numerous scientific journals. He has published a total of over 300 peer-reviewed papers abstracts and book chapters.

Biology of the Musculoskeletal System
Intracellular Signal Transduction Pathways Inflammation
Pro-inflammatory, Anti-Inflammatory & Anabolic Cytokines
Apoptosis
Matrix metalloproteinases
Osteoarthritis
Rheumatoid Arthritis
Fibromyalgia
Autoimmune Disorders

Jeffrey Isenberg earned his Bachelor’s at the University of Pennsylvania and completed his medical training at Tulane University School of Medicine, where he simultaneously earned a Masters of Public Health. He interned at Roosevelt-St. Luke’s Hospital and completed general surgery training at Staten Island University Hospital. He further specialized in reconstructive, hand and microsurgery with fellowship training at Yale University, the University of Connecticut and the University of Southern California. He then completed a post-doctoral research fellowship in the Laboratory of Pathology of the NCI, NIH funded by a Cancer Research Fellow Training Award. He worked as areconstructive microsurgeon

Enhancement of tissue blood flow, perfusion and wound healing and stem.

Deepak Shukla has received his Ph.D. in Microbiology and Immunology from the University of Illinois at Chicago (UIC) during the period of 1990-1996. Currently, he is working as the Marion Schenk Esq. Professor of Ocular Virology in the Departments of Ophthalmology &Visual Sciences and Microbiology & Immunology at UIC College of Medicine in Chicago, IL. He is also the Director of Ocular Virology Laboratory at UIC. He serves on the editorial boards of prestigious journals, has been a regular reviewer for over a dozen reputed scientific journals, and has authored over 50 peer-reviewed papers including publications in top rated journals such as Cell, Journal of Clinical Investigation, Journal of Cell Biology, Journal of Biological Chemistry etc. He has also written two book chapters and holds two international patents for his discoveries. He was the lead discoverer of 3-O sulfated heparan sulfate as the host cell membrane receptor for herpes simplex virus. He has received outstanding research awards from many organizations including American Herpes Foundation, Research to Prevent Blindness Inc. an

Cell biology of virus entry into human cells
Host cell membrane receptors for viruses such as herpes viruses.
Membrane receptors and membrane morphology facilitate viral infections.
Research on heparan sulfate proteoglycans
Studies on HVEM, a member of tumor necrosis factor receptor family and nectin-1 and a member of immunoglobulin superfamily.

Timothy B. Niewold is an Chairman of the Federation of Clinical Immunology Societies (FOCiS) Centers of Excellence, 2012-2015 Scientific Advisory Board Member, American College of Rheumatology Research and Education Foundation, 2012-2013 Medical-Scientific Advisory Council Member, Lupus Foundation of America, 2011-present Advisory Editor, Arthritis and Rheumatism Journal, 2010-2013 Associate Scientific Advisor, Science Translational Medicine Journal, 2011-2012

Type I interferon in autoimmune diseases
Heterogeneity in the molecular pathogenesis of autoimmune diseases
Genetic basis of lupus (systemic lupus erythematosus)

Michael G. Hanna is the founder of Vaccinogen and the discoverer and developer of OncoVAX® an autologous vaccine designed to provoke a specific immune response against colon cancer cells. His previous accomplishments include Chairman (Emeritus) and Chief Scientific Officer of Intracel Resources, Chief Operating Officer of Organon Teknika/Biotechnology Research Institute and Sr. Vice President of Organon Teknika Corporation. Prior to that (1975-1982) Michael G. Hanna was Director of the National Cancer Institute, Frederick Cancer Research Center. OncoVAX® is an autologous vaccine designed to provoke a specific immune response against colon cancer cells. The product is comprised of irradiated tumor cells obtained from the patient after surgery and it is administered along with the BCG vaccine. Vaccinogen believes OncoVAX® is the first product to show a significant reduction in recurrence of disease in Stage II colon cancer patients in a major, long-term clinical trial. Except for surgery, there is no medically accepted treatment for Stage II colon cancer. Trials using adjuvant chemotherapy have not demonstrated any patient benefit to date. He led the team that achieved FDA regulatory approval of TICE BCG for treatment of carcinoma in situ (CIS) bladder cancer. Worldwide registration was achieved in 1991 and it is standard of care for prophylaxis of recurrence of superficial bladder cancer and therapy of CIS. He received a doctoral degree in experimental pathology and immunology from the University of Tennessee. He has over 225 publications to his credit, has 11 patents in immunotherapy and has been the recipient of numerous honors, and served on many editorial boards

Vaccinogen, Inc.,
USA

Kota. V Ramana is a Professor at Department of Biochemistry and Molecular Biology at University of Texas Medical Branch, Galveston, TX, USA. He has received a Ph.D. in Biochemistry from the Postgraduate Institute of Medical Education and Research, Chandigarh, India in 1998. The chief objective of his investigations is to examine the involvement of oxidative stress signals in inflammation and to delineate the role of aldose reductase in the pathways used by activated macrophages and monocytes to control inflammation. He uses various genetic biochemical and cell biological approaches to analyze inflammatory responses regulated by aldose reductase in various inflammatory pathologies such as sepsis uveitis asthma and cancer. He is serving as an editorial board member of 6 other journals and reviewer of several journals.

Signal transduction in immune cells
Oxidative stress signaling in inflammatory complications
Role of polyol pathway enzymes in inflammatory pathologies

Jianfei Yang is a senior scientist and a project leader in the Th17/Treg cell company at Tempero Pharmaceuticals, a GSK company. He received a Ph.D. in Pathology from Niigata University School of Medicine in Japan in 1997. He then obtained postdoctoral training in Ken Murphy’s lab at HHMI and Washington University School of Medicine. In the past 15 years, he has been studying the role of CD4+ T helper cells in immunity and diseases. He has 10 years of experience in autoimmune disease research and pharmaceutical drug development. He has published numerous papers and patents. Currently, he is interested in targeting Th17 and/or Treg cells for the treatment of immunological diseases. He has published more than 100 technical papers in international conferences and journals.

Visual signal processing and multimedia networking.

Carina Venter is currently appointed as a Senior Research Fellow at the University of Portsmouth where she is doing a Post Doc in the area of Food Hypersensitivity (FHS). She recently completed her Ph.D. from the University of Southampton investigating the prevalence and incidence of FHS in childhood. She is also working as a Senior Dietitian at The David Hide Asthma and Allergy Research Centre where she sees adult and paediatric patients, as well as taking part in research.Carina graduated as a dietitian in South Africa in 1993. In 1997 she moved to the United Kingdom and worked at the Good Hope Hospital in Sutton Cold field before moving to the Isle of Wight. Her research career in Food Hypersensitivity started at the David Hide Centre followed by studying the Postgraduate Diploma in the Mechanisms and Management of Allergic Disease at the University of Southampton and she now lectures in this course. Carina is a member of the advisory board of Allergy. UK and deals regularly with nutritional queries from members of the public. She is also a member of the European Academy for Allergy and Clinical Immunology, the British Society for Allergy and Clinical Immunology, American Academy of Asthma, Allergy and Immunology and the British Dietetic Association as well as the UK representative of the American Overseas Dietetic Association. She has had a number of publications in international journals and has authored book chapters in FHS.

Food allergy, and food hypersensitivity

Ruo-Pan Huang is a founder and CEO of RayBiotech, Inc. and adjunct Associate Professor of Emory University. As a pioneer in the development of protein array technology, he and his team have developed many innovative protein array technologies and products which now are widely used worldwide by many investigators. He has published about 100 scientific research papers. He also serves on the editorial board of several journals such as Cancer Genomics and Proteomics, journal of analytical oncology and open journal of proteomics and on several other committees, including an NIH study section and Chinese National Natural Science Fund. His research has been funded by NIH, ACS, Emory University and others. During his tenure, he has received several awards, including the American Cancer Society Young Investigator Award.

Ray Biotech, Inc
USA

Sergei A. Grando is a board-certified dermatologist with more than 30 years experience. He is a leading expert and researcher in eczema and other autoimmune blistering diseases. He is conducting a clinical trial for the treatment of pemphigus with a non-hormonal medication. Grando has published more than 225 papers, monographs and book chapters, and has been awarded numerous research grants from the National Institutes of Health and other funding agencies. He was awarded as a Doctor of the Year, 2010, International Pemphigus and Pemphigoid Foundation and Vice Chair, a medical advisory board of the International Pemphigus and Pemphigoid Foundation. His Academic Distinctions includes 2010- present Vice Chair, Medical Advisory Board of International Pemphigus and Pemphigoid Foundation 2005-Honorary Chair for California, NRCC Physicians’ Advisory Board. 2004- Vice Chair, Dermatology Foundation of California 2002-present Honorary Member Ukrainian Association of Dermatologists, Venereologists, Cosmetologists, Ukraine 2001-Clinical Innovator Award, Flight Attendant Medical Research Institute, USA 1995-FIRST Award, NIH, NIAMS, USA and He have 250 publications.

University of California
USA

Jagat R. Kanwar is an immunologist and molecular biochemist with an international reputation in investigating fundamental and applied molecular aspects of cancer and chronic inflammation. He did his Ph.D. from Post Graduate Institute of Medical Education and Research, Chandigarh, India. Before joining Deakin University in 2006, he was a Senior Scientist/Senior Research Fellow in the University of Auckland, Auckland, New Zealand. During the past decade his research both academic and commercial has centered on understanding the pathophysiological mechanisms and/or finding treatments for a variety of chronic inflammatory diseases and different types of cancer. Kanwar has published 55 research articles, 12 invited reviews and 5 book chapters, in highly ranked, international, peer-reviewed journals. These publications have added to the body of knowledge in the fields of immunology, cancer gene therapy, nanomedicine, cell biology and biotechnology, and have extended these disciplines. He is a key inventor on 9 international patents and has provided consultancy to 5 Biotechnology based companies. He is a member of editorial board for 7 international journals and a nominated member of more than 12 national and international societies including American Society of Nanomedicine. He has extensive and close collaborations with colleagues from New Zealand, Australia, Singapore, India, China and USA.

Nanotechnology based drug delivery of proteins/peptides, siRNA and miRNA to target cancer and chronic inflammation.
Drug discovery for novel anticancer targets for cancer cell survival, death, arrest, and repair.
Development of immunomodulatory and anti-inflammatory bioactives, proteins and peptides for neuroprotection.
Development of complementary alternative medicine from the milk derived proteins including metal binding protein Lactoferrin, and herbal preparation derived active components with a special focus on the treatment of solid tumours colon and breast cancers.

Kenneth K. Wu is a Distinguished Chair Professor, National Taiwan University College of Medicine, Taiwan. Currently he is President, Distinguished Investigator and Acting Director for National Health Research Institutes, Taiwan. He received SANOFI Prize, SANOFI Association for Thrombosis Research and International Society of Thrombosis and Haemostasis in 1997. Previously he is Member in American Association of Physicians in 1997. He has number of publications in reputed journals.

Prostaglandin and nitric oxide synthesis and biological activities
Haemostatic and genetic risk of arterial thrombosis.
Identification and purification of endogenesis factors that central cyclooxygenase-2 (COX-2) expression in proliferating cells, elucidation of mechanisms by which salicylate inhibits transcriptional activation, and the novel actions of prostaglandins on adult cell and embryonic stem cell survival, differentiation and proliferation.

Jianguo Liu has completed his postdoctoral training at the Weill Medical College of Cornell University. He is currently tenured associate professor at Saint Louis University School of Medicine. He has published more than 40 peer-reviewed papers in reputed journals, serves on editorial boards of biomedical journals and as ad-hoc reviewer for many reputed scientific journals.

His primary research interest focuses on the interaction between cytokines produced in macrophages/DCs and T cell development in tumors and autoimmune diseases.

Kaihong Su obtained her doctorate degree and post-doctoral training from the University of Alabama at Birmingham (UAB). After being a faculty member at UAB for 5 years, she joined the University of Nebraska Medical Center in 2008 to continue her research. The long-term goal of her lab is to understand the molecular mechanisms for autoimmune diseases, including SLE and RA. She has published 26 papers in reputed journals and served as ad-hoc reviewer for a number of scientific journals.

Immunology
autoimmune diseases
autoantibodies and neutrophils

Lijuan Yuan has received Ph.D. in Immunology and Virology, 1996-2000. Food Animal Health Research Program, Department of Veterinary Preventive Medicine, Ohio Agriculture Research and Development Center OARDC, The Ohio State University. She was honored with Pfizer award at veterinary college´s 2011 Research Symposium. Currently, she held a position as Assistant Professor, Virology and Immunology. Center for Molecular Medicine and Infectious Diseases, Department of Biomedical Sciences and Pathobiology, College of Veterinary Medicine, Virginia Polytechnic Institute and State University, Blacksburg, VA.

Pathogenesis and innate and adaptive immune responses induced by enteric viruses (i.e. norovirus and rotavirus) in gnotobiotic pig models of human enteric virus infection and diseases, mechanism of immune modulation by probiotics,
The development of safer and more effective vaccines against viral gastroenteritis

Under the supervision of Dr. Aaron B. Waxman and Dr. Charles A. Hales, has been focused on understanding the mechanisms of acute lung injury against fungal and viral infections and non-infections. After completion of his postdoctoral training at Harvard Medical School, he joined as an assistant professor in the Nanomedicine Research Center-Division of Allergy and Immunology, Internal Medicine at University of south florida. He has published many peer-reviewed papers in top journals such as Journal of Immunology and Circulation research. He serves as a reviewer for numerous medical and pharmacological journals. His current research is funded by National Institute of Heath RO1 and American Heart Association.

Pathogen-Associated Molecular Patterns (PAMPs) and Danger-Associated Molecular Patterns (DAMPs);
viral and fungal infections of the lung;
pulmonary hemorrhage syndrome associated with dengue fever; and lung injury.

Esma S. Yolcu is Assistant Professor of Microbiology and Immunology, Director of Imaging Facility at the Institute for Cellular Therapeutics, and member of James Brown Cancer Center, University of Louisville, Louisville, KY. After receiving her Ph.D. from University of Ankara, Turkey, she joined the Institute for Cellular Therapeutics at the University of Louisville to pursue her postdoctoral training followed by promotion to a faculty position in the Department of Microbiology and Immunology. Her research focuses on the modulation of the immune system for the treatment of autoimmunity and graft rejection. Her work has been funded by various federal and nonfederal funding agencies, including NIH, American Heart Association, and American Diabetes Association. She is the recipient of several awards, member of various national and international societies, serves on Editorial Board of two scientific journals, and published over 67 peer-reviewed papers, abstracts, and review articles in high ranking journals, such as Immunity, Circulation, and Journal of Immunology.

Transplantation tolerance
bone marrow transplantation,
type 1 diabetes,
apoptosis graft versus host diseases,
Islet transplantation and heart transplantation

Jiansong Tong, is a research associate from Department of Cell Biology in The Scripps Research Institute at La Jolla, CA. He got his Ph.D. degree from Department of Biochemistry, Biophysics, and Molecular Biology in Iowa State University at Ames, IA in 2009. He completed his MS in Chinese Academy of Sciences in 2004 and my BS in Sichuan University in 2001. He has published four research papers on peer-reviewed scientific journals such as PNAS, JBC etc. Currently, he is a reviewer for several journals including Journal of Molecular Biology, Journal of Cellular and Molecular Medicine, Journal of Cancer Science etc.

Autoimmune response, inflammation signaling pathway, and TLR receptor

Charles J Malemud is Associate Director of the Rheumatology Fellowship Training Program at University Hospitals Case Medical Center Professor of Medicine Anatomy Division of Rheumatic Diseases Case Western Reserve University School of Medicine Cleveland Ohio. He received the Ph.D. in Experimental Pathology from the Department of Biology at George Washington University Washington DC 1969-1973. He completed his BS in Biology at Long Island University 1966. He was elected to James Shannon Award Who´s Who in Healthcare and Medicine. He is serving as an editorial board member of 9 reputed journals and a peer-reviewer for numerous scientific journals. He has published a total of over 300 peer-reviewed papers abstracts and book chapters.

Biology of the Musculoskeletal System Intracellular Signal Transduction Pathways Inflammation Pro-inflammatory, Anti-Inflammatory & Anabolic Cytokines Apoptosis Matrix metalloproteinases Osteoarthritis Rheumatoid Arthritis Fibromyalgia Autoimmune Disorders Research Interest

I am Oliver, Associate Professor in Unit for Laboratory Animal Medicine (ULAM) and Department of Microbiology and Immunology. I am also an affiliated member of the Center for Computational Medicine and Biology (CCMB) and a member of the (Comprehensive Cancer Center) in the University of Michigan (UM) Medical School. Our laboratory research is focused on host-Brucella interaction and bioinformatics. I had my D.V.M. education at Jiangxi Agricultural University and my M.S. degree (Co-advisors: Professors Zhongzhi Zhang and Hanchun Yang) in Infectious Diseases and Veterinary Preventive Medicine at China Agricultural University in China. I obtained my professional assistant veterinarian license during my two-year employment at Beijing Xijiao Livestock and Poultry Company, Beijing, China. My training in Brucella research started in 1996 in Dr. Gerhardt Schurig’s immunology laboratory at the Virginia Polytechnic Institute and State University (Virginia Tech). I obtained my Ph.D. in Dr. Schurig's lab in 2000. I then worked in the same lab as a postdoc for half a year. I obtained my M.S. degree (research advisor: Dr. Pedro Mendes) in computer science in Virginia Tech with a focus on bioinformatics in May 2002. After graduation I worked as a senior research associate for three years in Dr. Bruno Sobral’s group at the Virginia Bioinformatics Institute (VBI). I joined UM in July 2005 as an assistant professor and became an associate professor in September 2011 (with tenure).

Brucella microbiology and immunology research Vaccine Ontology Ontology of Adverse Events

Yehuda Shoenfeld is the founder and head of the Zabludowicz Center for Autoimmune Diseases, at the Sheba Medical Center which is affiliated to the Sackler Faculty of Medicine in Tel-Aviv University, in Israel. Dr. Shoenfeld is the Incumbent of the Laura Schwarz-Kipp Chair for Research of Autoimmune Diseases at the Tel-Aviv University. His clinical and scientific works focus on autoimmune and rheumatic diseases, and he has published more than 1700 papers in journals such as New Eng J Med, Nature, Lancet, Proc Nat Acad Scie, J Clin Invest, J Immunol, Blood, FASEB, J Exp Med, Circulation, Cancer and others. His articles have had over 31,000 citations. He has written more than three hundred and fifty chapters in books, and has authored and edited 25 books, some of which became cornerstones in science and clinical practice, such as "The Mosaic of Autoimmunity", "Infections and Autoimmunity" and the textbook "Autoantibodies" and "Diagnostic criteria of autoimmune diseases", all of which were published by Elsevier and sold by the thousands. He is on the editorial board of 43 journals in the field of rheumatology and autoimmunity and is the founder and the editor of the IMAJ (Israel Medical Association Journal) the representative journal of science and medicine in the English language in Israel, and also is the founder and Editor of the "Autoimmunity Reviews" (Elsevier) (Impact factor 6.6) and Co-Editor of "Journal of Autoimmunity" (Impact factor 7.4). For the last twenty years Dr. Shoenfeld has been the Editor of "Harefuah" The Israel journal in medicine (Hebrew) and he has edited the Israel Medical Encyclopedia (10 volumes, 5000 items). He had organized over 20 international congresses in autoimmunity. He is the editor-in-chief for Journal of Autoimmunity along with M. Eric Gershwin (University of California, Davis). According to the Journal Citation Reports, the journal has a 2012 impact factor of 8.145, ranking it 11th out of 137 journals in the category "Immunology”. This journal is a peer-reviewed medical journal covering research on all aspects of autoimmunity. It was established in 1988 and is published 8 times per year by Elsevier.

Autoimmune Diseases

Director of endocrinology at flinders medical centre with a conjoint position as professor of medicine at flinders university, nikolai petrovsky is also vice-president and secretary-general of the international immunomics society. active in diabetes, endocrinology and vaccine research, he is the founder of vaxine, a company funded by the us national institutes of health to develop novel vaccine technologies. in 2009 vaxine won the amp innovation award at the telstra business awards and australia's coolest company award from australian anthill magazine. nikolai petrovsky has developed vaccines against influenza, hepatitis b, sting allergy, malaria, japanese encephalitis, rabies and hiv, has authored over 90 papers and chapters and is a regular invited speaker at international vaccine conferences.

Pathogenesis of type 1 diabetes Obesity and type 2 diabetes Vaccine development Immuno-informatics

Michael G. Hanna is the founder of Vaccinogen and the discoverer and developer of OncoVAX® an autologous vaccine designed to provoke a specific immune response against colon cancer cells. His previous accomplishments include Chairman (Emeritus) and Chief Scientific Officer of Intracel Resources, Chief Operating Officer of Organon Teknika/Biotechnology Research Institute and Sr. Vice President of Organon Teknika Corporation. Prior to that (1975-1982) Michael G. Hanna was Director of the National Cancer Institute, Frederick Cancer Research Center. OncoVAX® is an autologous vaccine designed to provoke a specific immune response against colon cancer cells. The product is comprised of irradiated tumor cells obtained from the patient after surgery and it is administered along with the BCG vaccine. Vaccinogen believes OncoVAX® is the first product to show a significant reduction in recurrence of disease in Stage II colon cancer patients in a major, long-term clinical trial. Except for surgery, there is no medically accepted treatment for Stage II colon cancer. Trials using adjuvant chemotherapy have not demonstrated any patient benefit to date. He led the team that achieved FDA regulatory approval of TICE BCG for treatment of carcinoma in situ (CIS) bladder cancer. Worldwide registration was achieved in 1991 and it is standard of care for prophylaxis of recurrence of superficial bladder cancer and therapy of CIS. He received a doctoral degree in experimental pathology and immunology from the University of Tennessee. He has over 225 publications to his credit, has 11 patents in immunotherapy and has been the recipient of numerous honors, and served on many editorial boardsBiography

Cancer Vaccines

Lewellys F. Barker, MD, MPH, is currently Senior Medical Advisor at Aeras, a non-profit product development partnership based in Rockville, Maryland, which is conducting R&D on new TB vaccines. He served in the US Public Health Service as a medical research laboratory and clinical investigator and senior manager with the NIH Division of Biologics Standards and the US Food and Drug Administration Bureau of Biologics, and at the Division of AIDS of the US NIH/NIAID, with responsibilities for product development, regulation, and public health applications. He also worked as a Senior Vice President at the American Red Cross with responsibility for the Red Cross blood program. His major career activities have included preclinical and clinical research on viral (e.g., hepatitis, HIV, smallpox), rickettsial and bacterial (TB) vaccines, immune globulins and diagnostics for detection, treatment and prevention of infectious diseases. He is a graduate of Princeton University and Johns Hopkins University School of Medicine and School of Public Health and trained in Internal Medicine at the Johns Hopkins Hospital and New York University/Bellevue Hospital.

viral (e.g., hepatitis, HIV, smallpox) Rickettsial and bacterial (TB) vaccines Immune globulins and diagnostics for detection Treatment and prevention of infectious diseases.

Howard L. Kaufman is the Director of the Rush University Cancer Center. He also serves as an Associate Dean of the Rush University Medical Center and is Professor of Surgery, Internal Medicine-Medical Oncology, and Immunology & Microbiology at Rush University Medical College. Dr. Kaufman completed medical school at Loyola University in Chicago, surgical residency at Boston University and fellowship training in Tumor Immunology and Surgical Oncology at the National Cancer Institute in Bethesda, Maryland. He serves on several editorial boards and has published over 200 manuscripts, books, book chapters, review articles and abstracts. He is as a consultant to the NCI and several pharmaceutical and biotechnology companies and was recently appointed to the Board of Directors of the iSBTc. He has conducted over 50 clinical trials, including Phase I, II and III investigator-initiated, industry-sponsored, NIH-sponsored, cooperative group and multi-institutional studies related to the role of immunotherapy and surgical resection as treatment options for patients with melanoma and other cancers.Biography

Cancer immunotherapy Melanoma vaccines. Research Interest

Anil Shanker is an Associate Professor in the Biochemistry and Cancer Biology at Meharry Medical College. He is also a member of Vanderbilt-Ingram Comprehensive Cancer Center at Vanderbilt University. Dr.Shanker obtained his PhD from Banaras Hindu University in 1999. He performed his postdoctoral studies in tumor immunology at the CNRS/INSERM Center of Immunology, France and the National Cancer Institute,Maryland. His laboratory focuses on understanding functional cross-talk between T lymphocytes and natural killer cells and their activation signaling mechanisms in tumor models. He has over 30 research publications to his credit in cancer and immunology journals.

Host-Tumor Interactions and Thoracic/Head and Neck Cancer Research Functional cooperativity and signaling mechanisms in immune effector cells Tumor cell-death sensitizing and immunostimulatory agents in adoptive immunotherapy settings Pharmacological activation of Notch 1 signaling to enhance lymphocyte functions and overcome tumor-associated immunosuppression

Following a 5-year career as a Medical Laboratory Scientific Officer in histocompatability testing at the Royal Postgraduate Medical School London, I moved into academic research with Professor Barry Kay at the Brompton Hospital, London. This was followed by a year spent as a visiting Fellow at the Allergy Division, National Children's Hospital, Tokyo, Japan. I then returned to London and completed my PhD at the National Heart & Lung Institute, University of London, Brompton Hospital. A postdoctoral position with Colin Sanderson at the University of Oxford was followed by a move in 1992 to the Department of Medicine and Therapeutics, University of Leicester Medical School as a senior research fellow/honorary lecturer and later honorary senior lecturer. I was awarded a Wellcome Trust Career Development Fellowship in 1995 and joined the Department of Medicine and Therapeutics, University of Aberdeen as a Senior Lecturer in 1997 being appointed Reader in 2004. Visiting Professor of Immunity and Inflammation, Department of Clinical Medicine, Trinity College, Dublin. My research career in asthma and Allergy spans some 25 years and has resulted in the publication of over 150 papers, editorials and review articles in major international scientific and medical journals.

My major interests involve elucidation of the molecular mechanisms controlling the initiation and resolution of the inflammatory processes underlying asthmatic and allergic disease, with an emphasis on the role played by the cells of the bronchial epithelium and eosinophils together with expertise in the anti-inflammatory properties and potential side-effects of antihistamines.

Kaihong Su obtained her doctorate degree and post-doctoral training from the University of Alabama at Birmingham (UAB). After being a faculty member at UAB for 5 years, she joined the University of Nebraska Medical Center in 2008 to continue her research. The long-term goal of her lab is to understand the molecular mechanisms for autoimmune diseases, including SLE and RA. She has published 26 papers in reputed journals and served as ad-hoc reviewer for a number of scientific journals.Biography

Immunology autoimmune diseases autoantibodies and neutrophilsResearch Interest

Gregory Lee completed his Ph. D from California Institute of Technology and postdoctoral studies from University of California, San Diego. He became a full Professor at University of British Columbia in 1989, and retired in 2012 with the title of Professor Emeritus. He is the co-founder of Vancouver BioTech Ltd. He has published more than 200 papers, including 30 papers in cancer research. He has been serving as an editorial board member of the Journal of Carcinogenesis and Mutagenesis, and the Journal of Cancer Science and Therapy since 2012.

Research and Development of Antibody-Based Anti-Cancer Drugs. RP215 monoclonal antibody was shown to recognize specifically a carbohydrate-associated epitope located on the variable regions of cancer cell expressed immunoglobulins, designated in general as CA215.Structural elucidation of carbohydrate-associated epitope in CA215 which is recognized by RP215 monoclonal antibody (Mab). Humanizations of RP215 Mab for preclinical studies. Generations of Rat anti-idiotype Mabs as candidates for the development of anti-cancer vaccines in humans. Establishment of an Anti-GnRH receptor Mab, GHR106, as a substitute of short-acting GnRH analogs for antibody-based anti-cancer drugs, as well as preclinical studies. Elucidation of mechanisms of action for RP215 and GHR106 as antibody-based anti-cancer drugs. Elucidation of a carbohydrate-associated epitope recognized by RP215 monoclonal antibodies.

Michelle L. North, PhD, is a Post-Doctoral Fellow at Queen’s University, Kingston, Ontario, Canada. She is supported by an Ontario Ministry of Research and Innovation Post-Doctoral Fellowship Award, and her research focuses on epigenetics and the developmental origins of allergic disease. She is also involved in clinical studies in the Environmental Exposure Unit at Kingston General Hospital. Her research interests also include the relationship between air pollution and allergic disease. She completed her PhD at the University of Toronto, in the Institute of Medical Science, with specializations in Environment & Health and Biomedical Toxicology. Her doctoral thesis focused primarily on murine models of allergic airways inflammation and airways hyperresponsiveness and was supported by a Charles Best Canada Graduate Scholarship Doctoral Award.

Epigenetics Air pollution Ozone Arginase Nitric oxide synthase Developmental origins of allergy Atopy Cord Blood Murine models Airways hyperresponsiveness

Charles J Malemud received the PhD from George Washington University in 1973 and completed postdoctoral studies at the State University of New York at Stony Brook in 1977. He is Professor of Medicine & Anatomy in the Division of Rheumatic Diseases and Senior Investigator in the Arthritis Research Laboratory at Case Western Reserve University School of Medicine. He has published more than 200 papers and reviews primarily in the field of chondrocyte biology. He is on the editorial board of several rheumatology, immunology and musculoskeletal journals and is Editor-in-Chief of the Journal of Clinical and Cellular Immunology.

Biology of the Musculoskeletal System Intracellular Signal Transduction Pathways Inflammation Pro-inflammatory, Anti-Inflammatory & Anabolic Cytokines Apoptosis Matrix metalloproteinases Osteoarthritis Rheumatoid Arthritis Fibromyalgia Autoimmune Disorders Research Interest

Ahmed Hegazi (or Ahmed Gaffer Hegazi; احمد جعفر حجازى) (born May 31, 1948) is currently a Professor of Microbiology and Immunology in the department of Zoonotic Diseases, National Research Center, Egypt. Prof. Hegazi received his masters degree in 1979, and his PhD in 1981. Hegazi's research work has been focused lately on bee products and their therapeutic effects. Hegazi Organized and contributed to national and international research projects since 1977 and up till now; he has been the principal investigator on multiple research projects within the National Research Center. He has published 166 scientific papers and articles in national and international journals. He also served on the board of multiple national and international scientific journals. Dr. Hegazi is also the president of the Egyptian Environmental Society for Uses and Production of Bee Products, secretary of the Egyptian Society of Apitherapy, secretary general of the African Federation of Apiculture Associations, and a member of the International Apitherapy Commission (APIMONDIA). Awards First Class Decoration of Excellence, Egypt, 1995 The Senior Scientist Prize of National Research Center, Cairo, Egypt, 1996 The National Scientific Prize In Biological Sciences, Egypt, 1990 The Scientific Prize of The National Research Center, Cairo, Egypt, 1989 The Second Best Research Paper Award, International Congress of Propolis, Bones Airs, Argentina, 2000 Main Speaker Award,10th Academic Conference, PRA and NAS (Nippon Apitherapy Soc.) Japan, 2006 2 Bronze medals from The International Innovation Fair of the Middle East, Kuwait, 2007 Patents Patent No. 8901 at 22/08/2006: A novel drug from natural products with new therapeutic modalities in treatment of psoriasis Patent No. 1005 at 02/01/2006: A novel drug from natural resources for controlling Fascioliasis Patent No. 270: at 01/06/2005: A novel drug from medicinal plants with antiatherosclerotic (hypocholesterolaemic), antioxidant and cardio protective properties. Patent No. 272: at 01/06/2005: A novel drug from natural resources with antiatherosclerotic (hypocholesterolaemic), antioxidant and cardio protective properties. Scientific Activities Editor in the following International Journals: Research Journal of Allergy, 2007 International Journal of Virology, 2007 Current Research In Tuberculosis, 2007 Research Journal of Veterinary Science, 2007 Research Journal of Microbiology, 2007 International Journal of Cancer Research, 2007 Research Journal of Medicinal plants, 2007 Referee in the following International Journals: Journal of Planta Medica, 2005 Journal of Evidence Based Complementary and Alternative Medicine, 2006 International Journal of Radiation Biology, 2007

Apitherapy, Immunology

I am Oliver, Associate Professor in Unit for Laboratory Animal Medicine (ULAM) and Department of Microbiology and Immunology. I am also an affiliated member of the Center for Computational Medicine and Biology (CCMB) and a member of the (Comprehensive Cancer Center) in the University of Michigan (UM) Medical School. Our laboratory research is focused on host-Brucella interaction and bioinformatics. I had my D.V.M. education at Jiangxi Agricultural University and my M.S. degree (Co-advisors: Professors Zhongzhi Zhang and Hanchun Yang) in Infectious Diseases and Veterinary Preventive Medicine at China Agricultural University in China. I obtained my professional assistant veterinarian license during my two-year employment at Beijing Xijiao Livestock and Poultry Company, Beijing, China. My training in Brucella research started in 1996 in Dr. Gerhardt Schurig’s immunology laboratory at the Virginia Polytechnic Institute and State University (Virginia Tech). I obtained my Ph.D. in Dr. Schurig's lab in 2000. I then worked in the same lab as a postdoc for half a year. I obtained my M.S. degree (research advisor: Dr. Pedro Mendes) in computer science in Virginia Tech with a focus on bioinformatics in May 2002. After graduation I worked as a senior research associate for three years in Dr. Bruno Sobral’s group at the Virginia Bioinformatics Institute (VBI). I joined UM in July 2005 as an assistant professor and became an associate professor in September 2011 (with tenure).

Yongqun Oliver research interest are Brucella pathogenesis, vaccine research and development and Bioinformatics.

Yehuda Shoenfeld works at Sheba Medical Center in Tel HaShomer and the Sackler Faculty of Medicine at Tel-Aviv University. He is the incumbent of the Laura Schwarz-Kipp Chair for Research of Autoimmune Diseases. Shoefeld is the editor of two journals, Harefuah (Medicine) in Hebrew with English abstracts and Israel Medical Association Journal (IMAJ). He is editor-in-chief of Autoimmunity Reviews,[1] and co-editor of the Journal of Autoimmunity.[2] Head Zabludowicz Center for Autoimmune Diseases Incumbent of the Laura Schwarz-Kipp Chair for Research of Autoimmune Diseases Editor, Israel Medical Association Journal (IMAJ) Editor-in-chief of Autoimmunity Reviews Co-editor of the Journal of Autoimmunity Tel-Aviv University

Autoimmune Diseases, Immunomodulation Tel: (972)-3-5308070 Fax: (972)-3-5352855

Michael G. Hanna, Jr. received his PhD in experimental pathology and immunology from the University of Tennessee in 1964. He was on staff of the Oak Ridge National Laboratory, biology division from 1964-75. During this period he pioneered the early concepts of tumor immunology. He also served as a consultant with NASA for the lunar receiving laboratory during Apollo 11 and 12, for which his expertise in immunology was used in the testing of the lunar core powder for immunogenic or pathogenic materials. Dr. Hanna served during1975–83 as Director of the National Cancer Institute, Frederick Cancer Research Center (MD, USA). In this position he created a center of research excellence for the NCI and established the Biological Response Modifier Program which led in the development of resources for immunotherapy of cancer. He was Chief Operating Officer during 1984–94 of Organon Teknika/Biotechnology Research Institute and Senior Vice President of Organon Teknika Corporation, a subsidiary of Akzo Nobel, The Netherlands. He developed and obtained approvals for TICE BCG for the treatment of carcinoma in situ (CIS) bladder cancer, which remains the standard of care for prophylaxis of recurrence of superficial bladder cancer and therapy of CIS. Subsequently, Dr. Hanna founded PerImmune Inc., for which he served as President and Chief Executive Officer before it merged with Intracel Corp. in1998. He continued to work for Intracel Resources as Chief Scientific Officer and Chairman. In 2007, Dr. Hanna founded Vaccinogen Inc., where he served as Chairman and CEO. Currently, Dr. Hanna is Chairman Emeritus. The company is a pioneer in the field of cancer vaccines and is developing OncoVAX, an autologous vaccine designed to elicit a specific immune response against cancer cells. The Phase III vaccine is being investigated for treatment mainly of colon cancer, but also for melanoma and renal cell carcinoma. In addition to cancer therapy research and development, Dr. Hanna has been involved in Homeland Security. He served as Chairman of the Department of Commerce Biotechnology Advisory Committee (1984–9) and also participated in the Department of Defense Technical Working Group for Biotechnology (1988–9). PerImmune completed a Department of Defense contract to manufacture the current effective therapeutic for Botulinum toxin, an equine heptavalent anti-toxin. Dr Hanna’s research resulted in over 225 publications in international peer-reviewed journals and book chapters, and he holds 10 patents related to immunotherapy. Dr Hanna has been the recipient of numerous honors and awards and has serves on many editorial boards.

Immunology, Vaccines

James Mansfield is a scientist with over 25 years of experience in spectral imaging,in-vivo spectroscopy and applied data analysis, directed towards finding of novel optical methods for the diagnosis and monitoring of medical conditions. He is currently the Director of Quantitative Pathology Applications at PerkinElmer where he is the senior application scientist for their multispectral and digital pathology product lines. He is an associate editor of the American Journal of Nuclear Medicine and Molecular Imaging, holds 6 patents, has over 50 publications and has served as an invited speaker, session chair and organizer at a variety of international conferences.

Immunology

Yong Li, is an Associate Professor within the Department of Pediatric Surgery at the University of Texas, School of Medicine at Houston. He also is appointed as an Associate Professor in the Center for Stem Cell and Regenerative Medicine at The Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases (IMM) at The University of Texas Health Science Center at Houston. Dr. Li completed his MD and PhD training in China and was a general surgeon before he went to London in 1997. His first research position as a postdoctoral fellow was at the Imperial College School of Medicine in the UK (1997-1999), and later as a postdoctoral research associate at the Children’s Hospital of Pittsburgh of UPMC (1999-2002). He was promoted to a research assistant professor in 2002, assistant professor in 2004 (within tenure track system in 2006), and lead his research team to successful approaches in the field of stem cell and anti-fibrosis in regenerative medicine. These projects also include the enlargement and application of adult stem cells (muscle and skin) to repair traumatic injury (muscle, tendon, spinal cord and brain) and congenital diseases (DMD). They also began to study some projects such as the dedifferentiation process within skeletal muscle, cartilage and neuronal system of mammals and related aging research. As of 2011, Dr. Li has published over 66 refereed journal articles and review papers and five book chapters. He also serves as an associate editor or on the editorial board of five journals, and over five scientific communities including some grant reviewing boards. Dr. Li has won over twenty international awards for his scientific advances, including most recently, the Michael Miller Young Investigator Award at Children’s Hospital of UPMC. He is also a very successful grant-funded faculty member with grants from the National Institute of Health (NIH) and Department of Defense (DOD). He also is a great mentor and supervisor of students, medical residents and research fellows; several of his students and follows have won numerous national and international awards and scholarships including one student who won the 2011 National Goldwater Scholarship. Dr. Li is recognized as a leader in two scientific fields which include dedifferentiation related stem cell studies and fibrosis studies in tissue biomedical engineering. Within the newly established program in Children’s Regeneration Medicine at UTHealth, Dr. Li and his team has continual interest in investigating the fields of stem cells, fibrosis prevention and tissue engineering by using ground-breaking molecular and cellular biology techniques. Beside basic biomedical studies, Dr. Li will also conduct departmental projects in translational studies and clinical applications for utilizing stem cells and bioengineered tissues to repair congenital diseases of children such as diaphragmatic hernia and Duchenne muscular dystrophy (DMD).

Children’s Regenerative Medicine The project will use various cell sources combined with bioengineering scaffolds to build functional tissues for repair of pediatric defects, such as children’s diaphragmatic hernia Dedifferentiation and Stem Cell Populations The project aims to enlarge the stem cell pool without genetic modification as a cell source for regenerative medicine. Adult Embryonic Potential Stem Cells and Application Obtain natural embryonic potential stem cells from adult tissue for utilization in tissue engineering and regenerative medicine. Fibrosis and Prevention Studies Investigate the mechanism behind the fibrosis process after injuries and diseases, and seek methods for prevention of fibrous scar tissue formation

Jianfei Yang is a Principal Scientist and a project leader for a Th17 cell target at Tempero Pharmaceuticals, a GSK company, in Cambridge, MA, USA. He received a PhD in Pathology from Niigata University in Japan in 1997. He then obtained postdoctoral training in Dr. Ken Murphy’s lab at HHMI and Washington University. In the past 15 year, he has been studying the role of CD4+ T helper cells in immunity and diseases. He has more than 10 years of experience in autoimmune disease research and pharmaceutical drug development. He has published numerous papers and patents.

Immunology

Anil Shanker is an Associate Professor in the Department of Biochemistry and Cancer Biology at Meharry Medical College. He is also a member of Vanderbilt-Ingram Comprehensive Cancer Center at Vanderbilt University. Dr. Shanker obtained his PhD from Banaras Hindu University in 1999. He performed his postdoctoral studies at the CNRS/INSERM Center of Immunology, Marseille, France and the National Cancer Institute, Frederick, Maryland. His pioneering work with solid tumor models demonstrated that activated CD8 T cells provided a necessary “help” to dormant NK cells in eliciting their antitumor function. His laboratory is currently focused on understanding mechanisms of functional cross-talk between T cells and NK cells in tumor models. He is also dissecting the mechanisms of immunomodulation by the proteasome inhibitor bortezomib and Notch ligand DLL1 in adoptive T cell/NK cell transfer settings in an effort to design novel combinatorial immune strategies in cancer patients. He has over 30 research publications to his credit in cancer and immunology journals.

Tumor immunity and immunotherapy, T cell and NK cell biology, immune effector mechanisms, apoptosis signaling, thymic hormones, regulation of the innate and adaptive bidirectional cooperativity

Kaihong Su obtained her doctorate degree and post-doctoral training from the University of Alabama at Birmingham (UAB). After being a faculty member at UAB for 5 years, she joined the University of Nebraska Medical Center in 2008 to continue her research. The long-term goal of her lab is to understand the molecular mechanisms for autoimmune diseases, including SLE and RA. She has published 26 papers in reputed journals and served as ad-hoc reviewer for a number of scientific journals.Biography

Immunology autoimmune diseases autoantibodies and neutrophils Research Interest

John C. Cambier is Distinguished Professor and Chairman of Integrated Department of Immunology at University of Colorado Denver School of Medicine and National Jewish Health. He received his BS in 1970 from Southwest Missouri State University and MS in Virology in 1972 and PhD in 1975 from University of Iowa. He received National Research Service Award (NIH) in 1975 and Research Career Development Award (NIH) in 1982. In 2002, he received Outstanding Scientific Achievement Award (NJMRC).

Immunology
Tolerance and autoimmunity
Immune responses

Jin Wang is an Associate Professor in the Department of Pathology & Immunology at University of Southern California, USA. He has published many scientific papers.

Molecular regulation of immune responses by apoptosis and autophagy Apoptosis pathways in lymphocytes

Upon completion of a MD degree at Beijing Medical University and a PhD degree in Pathology at the University of Wisconsin Madison. 1998 Dr. Yin pursued her clinical residency training in Anatomic Pathology and Clinical Pathology followed by two fellowships in Hematopathology and Molecular Genetic Pathology respectively at the University of Texas MD Anderson Cancer Center MDACC. She is board certified by the American Board of Pathology in Anatomic Pathology Clinical Pathology Hematology and Molecular Genetic Pathology Dr. Yin is currently an assistant professor at the Department of Hematopathology at MDACC and an assistant professor at Graduate School of Biomedical Science at the University of TexasHouston. In addition to clinical service and fellowship and postdoc education Dr. Yin has been actively participating multiple research projects in leukemia and lymphoma which has led to over 50 research papers editorial reviews and book chapters. She is serving as reviewers for over 10 journals.

Mechanisms of imatinib resistance in patients with chronic myelogenous leukemiaMolecular monitoring of responses to kinase inhibitors in chronic myelogenous leukemiaClinical, morphologic and molecular genetic features of acute myeloid leukemia Immunoglobulin gene rearrangement in acute myeloid leukemiaClinical, morphologic and molecular genetic features of a variety of lymphomasMolecular markers as a tool in the diagnosis, targeted therapy and prognosis in cancer.

Nurieva Roza Insafetdinovna is an assistant professor in the Department of Immunology at MD Anderson Cancer Center, USA. She has more than 30 publications.

Immunology

Professor Paul Foster is the Director of the Priority Research Centre for Asthma and Respiratory Disease; the Virus, Infection/Immunity, Vaccines and Asthma Program, Hunter Medical Research Institute and the Cooperative Research Centre (CRC) for Asthma and Airways (Newcastle node). He also currently holds the Chair of Immunology, School of Biomedical Sciences and Pharmacy, Faculty of Health, University of Newcastle. He is also a visiting Professor at Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.He serves as an Associate Editor of the American Journal of Respiratory Cell and Molecular Biology and the Journal of Pharmacology and Therapeutics, and is on the Editorial Boards of a number of leading international immunology/allergy journals. Professor Foster's research focuses on understanding the molecular and cellular basis of asthma, allergy, respiratory disorders, and chronic inflammation. His research program focuses on translational approaches directed towards the development of novel anti-inflammatory therapies. Professor Foster's research findings are published in the most highly ranked medical and biomedical science journals (e.g. Nature Immunology and Journal of Experimental Medicine). Essential Science Indicators metrics places his team on the forefront of his field internationally. Professor Foster receives numerous and ongoing invitations to speak and chair sessions and leading international conferences in immunology and respiratory medicine.

Professor Paul Foster research interest is cellular and molecular processes that underlie the development of allergic disease (lung, skin and gastrointestinal tract) and of viral (RSV and influenza) induced pulmonary inflammation,Professor Foster's team particularly interested in the molecular events that predispose to remodeling of the airways in chronic disease and the subsequent impact on lung function. In particular, projects are focusing on the biology of CD4+ Th2 cells, CD8+ T cells and eosinophils, and in signaling arrangements between cytokine and chemokine systems that pertain to allergic disease, viral induced pathogenesis and viral induced exacerbation of asthma.

Simona Di Francesco is the Director of Urological, Biomedical and Translational Sciences Department. People's University Nicolaus Copernicus , Cassino (RM) ,Italy 2014 M.D , PhD. People's University Nicolaus Copernicus , Cassino (RM) ,Italy 2014 PhD Degree in Clinical and Experimental Medicine and Surgery (CEMS), School of Advanced Studies , Department of Medicine and Aging, University “G. D’Annunzio” Chieti-Pescara. Doctoral Thesis : Metabolic Alterations and Vascular Damage in Prostate Cancer. 2012 AWARD-PIERRE FABRE-CIFU, Italian Society of Urology. 2012 Project Planning Course , G. D’Annunzio University of Chieti-Pescara, School of Advanced Studies. 2012 Advanced English Course For Special Purposes. G. D’annunzio University. School of Advanced Studies. 2012 Course Of Scientific English "Writing Across Science”, G. D’annunzio University, School of Advanced Studies, Nazareth College. 2011 Course Scientific English - Uda-Learning , G. D’Annunzio University of Chieti-Pescara. 2010 Specialization in Urology, G. D’Annunzio University of Chieti-Pescara, with maximum marks cum laude. 2009 Specialization in Internist Echography, G. D’Annunzio University of Chieti-Pescara. 2004 Urostage: Kidney , Prostate, Urinary Bladder. University “G. D’Annunzio” Chieti-Pescara, Department of Medicine and Aging, Section of Urology. 2001 XIV International Course of Digestive and Endocrine Surgery. University “G. D’Annunzio” Chieti-Pescara, School of Medicine and Surgery, Italy. 2001-2002 M.D, G.D’Annunzio University of Chieti-Pescara, Medicine and Surgery.

Simona Di Francesco research interest is in Urological Cancer and Immunology, Prostate and Immunology, Bladder and Immunology, Kidney and Immunology.

Jennifer Wu Received PhD from the University of British Columbia in Canada, post-doc trained at Fred Hutchinson Cancer Research Center. Accepted a faculty position at the University of Washington, and moved to the MUSC/Hollings Cancer Center in 2011. Currently serving as the Committee chair for Cancer COP of FOCIS, Editorial board of Frontier Immunology (Tumor Immunology), Frontier Oncology, Journal of Molecular and Genetic Medicine, American Journal of Immunology, Austin Journal of Clinical immunology, and Editor-in-Chief for the Journal of Inflammation and Cancer newly lunched by Versita.

Jennifer Wu's research interest is on the molecular and cellular regulation of host immunity and inflammatory responses in tumor microenvironment by tumor secretive soluble elements, with emphasis on tumor shed proteins and secretive cytokines. One of mechanisms conveying tumor immune surveillance in cancer patients is though induced expression of the membrane-bound MHC I chain related molecules A and B (MICA and MICB) on tumor cell surface. These molecules serve as ligands for the immune activating receptor NKG2D to signal the activation of NK and CD8 T cell anti-tumor responses.

Sedigheh Zakeri graduated with a first class honors degree in Biological Science from the University of Mashhad in 1989 and obtained her M.Sc and PhD in Parasite Immunology from Liverpool School of Tropical Medicine in 1994 and 1998, respectively. She joined Parasitology Department in Pasteur Institute of Iran in 1999 and a year later moved to Biotechnology Department, where initiated immune-molecular research on malaria through her re-entry grant awarded by WHO/TDR. Since 2005, Malaria and Vector Research Group (MVRG) established by her and Prof. Navid Dinparast Djadid as an independent research group in Biotechnology Research Center. She is currently Head of the MVRG.

Professor S. Zakeri area of interest is Malaria Immunology and vaccine development.Vaccines could be a crucial component of efforts to eradicate malaria. Continued support for these efforts is essential, but, if malaria vaccines are to be used as part of a repertoire of tools for elimination or eradication of malaria, they will need to have an impact on malaria transmission. Her interest is on "vaccines that interrupt malaria transmission" (VIMT), which not only include "classical" transmission-blocking vaccines but also pre-erythrocytic and asexual stage vaccines that have an effect on transmission. Currently, Prof Zakeri main activities are on “Oral Vaccine Delivery using Microalgae" and the most potent adjuvant for the development of an oral vaccine against malaria in developing countries.

Dr. SangKon Oh received his PhD degree at the Johns Hopkins University in 2000 and trained at National Cancer Center (NCI, NIH) as a postdoctoral fellow by 2002. He worked as an IPA fellow at NCI in association with the Johns Hopkins University from 2002 to 2005. Dr. Oh joined BIIR in 2005. He is also affiliated with Baylor University at Waco, TX, as an Associate Professor.

Dr. Sangkon Oh research interests are in the area of molecular and immunological functions of DC surface receptors expressed on different subsets of human dendritic cells in healthy and patients. Dr. Oh laboratory has uncovered novel immunological functions of several DC surface lectins, e.g. DC-ASGPR and LOX-1, in controlling host immune responses toward either immunity or tolerance. Dr. Oh’s laboratory has also discovered that monocytes and subsets of DCs in lupus patients express distinct patterns of surface receptors, which could help us understand the mechanisms in which DCs break B cell tolerance in lupus.

Mr. De la Parra-Solomon is an entrepreneur focused on Information Technology, Education and Health. He is creative, results-driven and has 16+ years of Digital Strategy experience in architecture and implementation. Mr. De la Parra-Solomon is the Chief Strategy Officer and Co-Founder of the Quantum Brain Research Institute (www.quantumbrain.institute), a HealthTech initiative established in Tallinn, Estonia focused on Mental Health and Information Technology solutions.

HealthTech

Ms. Susanna Uusmaa is a biomedical scientist with broad expertise in Medical Sciences and in International Business. Holding an MSBS degree, she is result-driven to integrate modern smart technologies into making substantive contributions to the biomedical sector. Having conducted research in neuroscience and oncology and having proudly graduated from Tallinn University of Technology (TALTECH) and Tallinn University School of Natural Sciences and Health, Ms. Uusmaa takes an evidence-based approach to her professional objectives and also to her endeavors as a passionate healthy lifestyle entrepreneuse. With a background in biomolecular and medical sciences, she has recently co-founded Quantum Brain Research Institute ( https://quantumbrain.institute/ )with the aim of supporting the development of neuroscientific research for neurocritical treatment applications through instructive programs in mental health assessment and management.

neuroscience and oncology

Segundo Mesa Castillo. As Specialist in Neurology, he worked for 10 years in the Institute of Neurology of Havana, Cuba. He has worked in Electron Microscopic Studies on Schizophrenia for 32 years. He was awarded with the International Price of the Stanley Foundation Award Program and for the Professional Committee to work as a fellowship position in the Laboratory of the Central Nervous System Studies, National Institute of Neurological Diseases and Stroke under Dr. Joseph Gibbs for a period of 6 months, National Institute of Health, Bethesda, Maryland, Washington D.C. USA, June 5, 1990.

Neurology